Peter Williams

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

David A. Margolis, Juan González‐García, Hans-Jürgen Stellbrink et al. · The Lancet · 2017 · 492 citations

Treatment And Prevention, Medicine, Phase 2B +8

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial

David A. Margolis, Cynthia Brinson, Graham Smith et al. · The Lancet Infectious Diseases · 2015 · 198 citations

Phase 2B, Human Retrovirus, Pharmacology +10

Pharmacokinetics, Safety, and Tolerability With Repeat Doses of GSK1265744 and Rilpivirine (TMC278) Long-Acting Nanosuspensions in Healthy Adults

William Spreen, Peter Williams, David M. Margolis et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2014 · 114 citations

Randomised clinical trial: palliative long‐term abdominal drains vs large‐volume paracentesis in refractory ascites due to cirrhosis

Lucia Macken, Stephen Bremner, Heather Gage et al. · Alimentary Pharmacology & Therapeutics · 2020 · 59 citations · Full text

Digital health information provision and health outcomes

David Nicholas, Paul Huntington, Peter Williams et al. · Journal of Information Science · 2001 · 41 citations

Engineering, Health Outcome, Information Seeking +22